{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:06:02Z","timestamp":1792706762894,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Res Cardiol"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Lately, mavacamten emerged as a new therapeutic option for symptomatic patients with obstructive hypertrophic cardiomyopathy (oHCM). Clinical trials revealed reduction of serum biomarkers, and left ventricular outflow tract (LVOT) obstruction, as well as an improvement in clinical symptoms and exercise capacity. Nevertheless, clinical experience and manageability of patients in a real-world setting is still lacking.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material and methods<\/jats:title>\n                    <jats:p>22 patients with symptomatic oHCM (54.5% male, age 58.5\u2009\u00b1\u200916.2\u00a0years) and elevated LVOT gradients were started on mavacamten between March 2023 and June 2024. All patients were New York Heart Association (NYHA) class II or higher. Seven patients were excluded from primary analysis due to comedication with Angiotensin-converting-enzyme-inhibitors or Angiotensin-II receptor blockers. Cardiac imaging, laboratory work-up and clinical evaluation were assessed at three visits during the 12\u00a0weeks initiation phase; Dosing of mavacamten was adjusted according to manufacturer\u2019s recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>At 12\u00a0weeks, the majority of patients described a significant improvement of their quality of life. Work-up at 12\u00a0weeks revealed a significant reduction of serum biomarkers and LVOT gradients. In four patients, mavacamten needed to be temporarily paused due to clinical complaints or transient left ventricular ejection fraction deterioration below 50% with subsequent full recovery.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We provide first insights into the usage of mavacamten in oHCM patients during the titration period in a real-world setting. Clinical findings are in line with previous clinical trials. In accordance with current recommendations, we highlight the need for standardized follow-up of patients on mavacamten treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00392-024-02544-w","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T07:02:13Z","timestamp":1728370933000},"page":"725-731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Real-world experience in initiation of treatment with the selective cardiomyosin inhibitor mavacamten in an outpatient clinic cohort during the 12-week titration period"],"prefix":"10.1007","volume":"115","author":[{"given":"Finn","family":"Becker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Novotny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Clau\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"M\u00f6ller-Dyrna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birge","family":"Specht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Orban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Massberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8824-3581","authenticated-orcid":false,"given":"Stefan","family":"K\u00e4\u00e4b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Reichart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"issue":"25","key":"2544_CR1","doi-asserted-by":"publisher","first-page":"e558","DOI":"10.1161\/CIR.0000000000000937","volume":"142","author":"SR Ommen","year":"2020","unstructured":"Ommen SR, Mital S, Burke MA et al (2020) 2020 AHA\/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice [published correction appears in Circulation. 2020 Dec 22;142(25):e633]. Circulation 142(25):e558\u2013e631. https:\/\/doi.org\/10.1161\/CIR.0000000000000937","journal-title":"Circulation"},{"issue":"37","key":"2544_CR2","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR et al (2023) 2023 ESC guidelines for the management of cardiomyopathies. Eur Heart J 44(37):3503\u20133626. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194","journal-title":"Eur Heart J"},{"issue":"6273","key":"2544_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1126\/science.aad3456","volume":"351","author":"EM Green","year":"2016","unstructured":"Green EM, Wakimoto H, Anderson RL et al (2016) A small-molecule inhibitor of sarcomere contractility suppresses hypertrophic cardiomyopathy in mice. Science 351(6273):617\u2013621. https:\/\/doi.org\/10.1126\/science.aad3456","journal-title":"Science"},{"issue":"10253","key":"2544_CR4","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","volume":"396","author":"I Olivotto","year":"2020","unstructured":"Olivotto I, Oreziak A, Barriales-Villa R et al (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial [published correction appears in Lancet. 2020 Sep 12;396(10253):758]. Lancet 396(10253):759\u2013769. https:\/\/doi.org\/10.1016\/S0140-6736(20)31792-X","journal-title":"Lancet"},{"issue":"11","key":"2544_CR5","doi-asserted-by":"publisher","first-page":"741","DOI":"10.7326\/M18-3016","volume":"170","author":"SB Heitner","year":"2019","unstructured":"Heitner SB, Jacoby D, Lester SJ et al (2019) Mavacamten treatment for obstructive hypertrophic cardiomyopathy: a clinical trial. Ann Intern Med 170(11):741\u2013748. https:\/\/doi.org\/10.7326\/M18-3016","journal-title":"Ann Intern Med"},{"key":"2544_CR6","volume-title":"CAMZYOS (mavacamten): prescribinginformation","author":"US Food and Drug Administration","year":"2022","unstructured":"US Food and Drug Administration (2022) CAMZYOS (mavacamten): prescribinginformation. US Food and Drug Administration, Silver Spring"},{"key":"2544_CR7","unstructured":"European Medicines Agency (2023) CAMZYOS (mavacamten), https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/camzyos. Accessed 20 Mar 2024"},{"issue":"12","key":"2544_CR8","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/cpdd.1332","volume":"12","author":"V Perera","year":"2023","unstructured":"Perera V, Gretler DD, Seroogy JD, Chiang M, Palmisano M, Florea V (2023) Effects of omeprazole and verapamil on the pharmacokinetics, safety, and tolerability of mavacamten: two drug-drug interaction studies in healthy participants. Clin Pharmacol Drug Dev 12(12):1241\u20131251. https:\/\/doi.org\/10.1002\/cpdd.1332","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2544_CR9","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ahj.2011.09.027","volume":"163","author":"KE Flynn","year":"2012","unstructured":"Flynn KE, Lin L, Moe GW, Howlett JG, Fine LJ, Spertus JA, McConnell TR, Pina IL, Weinfurt KP (2012) Relationships between changes in patient-reported health status and functional capacity in outpatients with heart failure. Am Heart J 163:88-94.e3","journal-title":"Am Heart J"},{"issue":"1","key":"2544_CR10","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jchf.2023.09.028","volume":"12","author":"F Rader","year":"2024","unstructured":"Rader F, Or\u0119ziak A, Choudhury L et al (2024) Mavacamten treatment for symptomatic obstructive hypertrophic cardiomyopathy: interim results from the MAVA-LTE study, EXPLORER-LTE cohort. JACC Heart Fail 12(1):164\u2013177. https:\/\/doi.org\/10.1016\/j.jchf.2023.09.028","journal-title":"JACC Heart Fail"},{"issue":"5","key":"2544_CR11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4414\/cvm.2016.00415","volume":"19","author":"K Witzel","year":"2016","unstructured":"Witzel K, Muench J, Patten M (2016) Influence of RAAS inhibition on outflow tract obstruction in hypetrophic cardiomyopathy. Cardiovascular Medicine 19(5):152\u2013156","journal-title":"Cardiovascular Medicine"},{"issue":"37","key":"2544_CR12","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","volume":"44","author":"E Arbelo","year":"2023","unstructured":"Arbelo E, Protonotarios A, Gimeno JR et al (2023) 2023 ESC guidelines for the management of cardiomyopathies: developed by the task force on the management of cardiomyopathies of the European Society of Cardiology (ESC). Eur Heart J 44(37):3503\u20133626. https:\/\/doi.org\/10.1093\/eurheartj\/ehad194","journal-title":"Eur Heart J"},{"key":"2544_CR13","doi-asserted-by":"publisher","first-page":"1403422","DOI":"10.3389\/fcvm.2024.1403422","volume":"11","author":"AA Derda","year":"2024","unstructured":"Derda AA, Abelmann M, Sonnenschein K et al (2024) Discontinuation of afterload-reducing drugs decreases left ventricular outflow tract obstruction in hypertrophic obstructive cardiomyopathy. Front Cardiovasc Med 11:1403422. https:\/\/doi.org\/10.3389\/fcvm.2024.1403422","journal-title":"Front Cardiovasc Med"}],"container-title":["Clinical Research in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02544-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00392-024-02544-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-024-02544-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T06:55:53Z","timestamp":1776236153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00392-024-02544-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2544"],"URL":"https:\/\/doi.org\/10.1007\/s00392-024-02544-w","relation":{},"ISSN":["1861-0684","1861-0692"],"issn-type":[{"value":"1861-0684","type":"print"},{"value":"1861-0692","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"30 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FB received travel expenses covered by Bristol Myers Squibb, FB and SK received speaker honorarium from Bristol Myers Squibb. All other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All patients signed informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}